Neurocrine(NBIX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance ® INGREZZA (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26$2.30 - $2.32 Billion ® Board Authorizes$300 Million Share Repurchase Plan SAN DIEGO, October 30, 2024 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended ...